Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: Beyond cardiovascular diseases

被引:6
作者
Calabro P. [1 ]
Yeh E.T.H. [1 ]
机构
[1] Department of Cardiology, Univ. Texas-MD Anderson Cancer Ctr., Houston, TX 77030-4095
关键词
Acute Myeloid Leukemia; Statin; Simvastatin; Pravastatin; Lovastatin;
D O I
10.1007/s11883-004-0114-6
中图分类号
学科分类号
摘要
Statins can profoundly affect cellular metabolism by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, which is the rate-limiting enzyme responsible for cholesterol synthesis. Many physicians prescribe statins to lower plasma cholesterol levels, which has beneficial effects in both the primary and secondary prevention of coronary artery disease. However, in vitro, in vivo, animal, and clinical studies have all shown that statins may also have important pleiotropic properties. In fact, a number of clinical studies have suggested that statins are involved in modulating diseases such as cancer, osteoporosis, and dementia (including Alzheimer's disease). However, because these studies have been only preliminary and observational in nature, large randomized, placebo-controlled studies are needed to confirm the modulatory role of statins in these important diseases. Copyright © 2004 by Current Science Inc.
引用
收藏
页码:36 / 41
页数:5
相关论文
共 57 条
[51]  
Sugiyama M., Kodama T., Konishi K., Et al., Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells, Biochem. Biophys. Res. Commun., 271, pp. 688-692, (2000)
[52]  
Sirola J., Honkanen R., Kroger H., Et al., Relation of statin use and bone loss: A prospective population-based cohort study in early postmenopausal women, Osteoporosis Int., 13, pp. 537-541, (2002)
[53]  
Chan K.A., Andrade S.E., Boles M., Et al., Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women, Lancet, 355, pp. 2185-2188, (2000)
[54]  
Meier C.R., Schlienger R.G., Kraenzlin M.E., Et al., HMG-CoA reductase inhibitors and the risk of fractures, JAMA, 283, pp. 3205-3210, (2000)
[55]  
Wang P.S., Solomon D.H., Mogun H., Et al., HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients, JAMA, 283, pp. 3211-3216, (2000)
[56]  
Pedersen T.R., Kjekshus J., Statin drugs and the risk of fracture, JAMA, 284, pp. 1921-1922, (2000)
[57]  
Reid I.R., Hague W., Emberson J., Et al., Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease, Lancet, 357, pp. 509-512, (2001)